MBX Biosciences Engages in Major Virtual Forum
MBX Biosciences, Inc. (NASDAQ: MBX), a company dedicated to creating innovative precision peptide therapies for endocrine and metabolic disorders, has confirmed its participation in a significant upcoming event. The firm's President and CEO, Kent Hawryluk, alongside Chief Medical Officer, Dr. Sam Azoulay, will partake in a fireside chat during the Stifel 2025 Virtual Cardiometabolic Forum.
Details of the Stifel 2025 Virtual Cardiometabolic Forum
This much-anticipated event is set to take place on September 30. The key highlights for the presentation include:
Forum Highlights
Date: Tuesday, September 30
Format: Fireside chat
Time: 10:00 a.m. – 10:25 a.m. ET
Location: Virtual
Those interested can access the live webcast via the events section on MBX's official website. A replay of the discussion will be accessible shortly after the event's conclusion and will remain available for about three months.
Understanding MBX Biosciences' Pursuits
MBX Biosciences specializes in pioneering biopharmaceutical advancements focused on addressing critical health challenges. They anchor their development efforts on a proprietary platform aimed at crafting precision peptide therapies tailored for endocrine and metabolic conditions.
Pipeline Overview
The company is currently advancing a promising pipeline targeting unmet medical needs with several pipeline candidates. These include:
- Canvuparatide (MBX 2109): In Phase 2 development for chronic hypoparathyroidism (HP).
- Imapextide (1416): Currently in Phase 2 for post-bariatric hypoglycemia (PBH).
- Obesity Portfolio: This includes MBX 4291, which is in Phase 1, alongside multiple discovery and pre-clinical candidates aimed at obesity-related conditions.
The Importance of Their Mission
MBX Biosciences seeks to make a significant impact on patient health by developing therapeutics that cater to substantial medical gaps in the treatment of metabolic and endocrine disorders. Their strategic focus on clinically validated targets showcases their commitment to not just meeting but exceeding expectations in the biopharmaceutical sector.
Company Background and Contact Information
Based in Carmel, Indiana, MBX Biosciences is at the forefront of biopharmaceutical innovation. Those wishing to learn more about their endeavors can visit their website.
Contact Details
Media Contact:
Katie Beach Oltsik
Inizio Evoke Comms
Email: katie.beach@inizioevoke.com
Phone: (937) 232-4889
Investor Contact:
Jim DeNike
MBX Biosciences
Email: jdenike@mbxbio.com
Frequently Asked Questions
What is the focus of MBX Biosciences?
MBX Biosciences concentrates on discovering and developing precision peptide therapies for endocrine and metabolic disorders.
When is the Stifel 2025 Virtual Cardiometabolic Forum?
The forum is scheduled for September 30, and MBX Biosciences will participate in a fireside chat during the event.
How can I watch the MBX Biosciences presentation?
You can access the live webcast of the presentation through the events section of MBX's official website.
What are some key products in MBX's pipeline?
Notable products include MBX 2109 for chronic hypoparathyroidism and imapextide for post-bariatric hypoglycemia.
Where is MBX Biosciences located?
MBX Biosciences is based in Carmel, Indiana.